- Home
- CMMB vs IMRN Comparison
CMMB vs IMRN Comparison
Compare CMMB & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- IMRN
- Stock Information
- Founded
- CMMB 2004
- IMRN 1994
- Country
- CMMB Israel
- IMRN Australia
- Employees
- CMMB N/A
- IMRN N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- CMMB Health Care
- IMRN Health Care
- Exchange
- CMMB Nasdaq
- IMRN Nasdaq
- Market Cap
- CMMB 13.8M
- IMRN 14.4M
- IPO Year
- CMMB N/A
- IMRN N/A
- Fundamental
- Price
- CMMB $2.54
- IMRN $1.74
- Analyst Decision
- CMMB Strong Buy
- IMRN
- Analyst Count
- CMMB 2
- IMRN 0
- Target Price
- CMMB $26.50
- IMRN N/A
- AVG Volume (30 Days)
- CMMB 80.5K
- IMRN 389.2K
- Earning Date
- CMMB 11-20-2025
- IMRN 08-29-2025
- Dividend Yield
- CMMB N/A
- IMRN N/A
- EPS Growth
- CMMB N/A
- IMRN N/A
- EPS
- CMMB N/A
- IMRN N/A
- Revenue
- CMMB N/A
- IMRN $4,777,422.00
- Revenue This Year
- CMMB N/A
- IMRN N/A
- Revenue Next Year
- CMMB N/A
- IMRN N/A
- P/E Ratio
- CMMB N/A
- IMRN N/A
- Revenue Growth
- CMMB N/A
- IMRN 48.63
- 52 Week Low
- CMMB $2.36
- IMRN $1.42
- 52 Week High
- CMMB $9.84
- IMRN $2.48
- Technical
- Relative Strength Index (RSI)
- CMMB 42.45
- IMRN 49.05
- Support Level
- CMMB $2.36
- IMRN $1.47
- Resistance Level
- CMMB $2.85
- IMRN $1.77
- Average True Range (ATR)
- CMMB 0.20
- IMRN 0.10
- MACD
- CMMB -0.02
- IMRN 0.03
- Stochastic Oscillator
- CMMB 32.71
- IMRN 91.53
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.